Nevertheless, a universally valid cutoff for all cancers to classify patients into high and low TMB has not been established for WES, although a TMB of 10 mutations/Mb, as determined by the FoundationOne CDx assay, has been FDA-approved as the threshold for treating all solid tumors with programmed cell death protein 1 inhibitors. The gene discussed is PDCD1; the disease is cancer.